Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.2%

5 terminated/withdrawn out of 41 trials

Success Rate

82.8%

-3.7% vs industry average

Late-Stage Pipeline

24%

10 trials in Phase 3/4

Results Transparency

8%

2 of 24 completed trials have results

Key Signals

6 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
19(50.0%)
Phase 1
8(21.1%)
Phase 3
8(21.1%)
Phase 4
2(5.3%)
Early Phase 1
1(2.6%)
38Total
Phase 2(19)
Phase 1(8)
Phase 3(8)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (41)

Showing 20 of 41 trials
NCT06075706Phase 2Active Not Recruiting

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Role: lead

NCT03156790Phase 2Terminated

PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia

Role: lead

NCT04195633Phase 2Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Role: collaborator

NCT04738162Phase 2Completed

Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors

Role: collaborator

NCT02349906Phase 2Completed

Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

Role: lead

NCT05534620Phase 1Recruiting

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Role: lead

NCT06781879Phase 4Recruiting

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

Role: collaborator

NCT07025824Phase 2Not Yet Recruiting

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Role: collaborator

NCT06239311Phase 3Recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Role: lead

NCT04629833Phase 3Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Role: lead

NCT04469699Phase 2Terminated

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Role: collaborator

NCT03254589Phase 4Completed

Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Role: collaborator

NCT01848028Recruiting

PsoBest - The German Psoriasis Registry

Role: collaborator

NCT02203760Phase 2Active Not Recruiting

Pazopanib Vs. Pazopanib Plus Gemcitabine

Role: collaborator

NCT01063647Phase 1Completed

Dose-range Finding Treosulfan-based Conditioning

Role: lead

NCT01582048Phase 2Terminated

Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Role: collaborator

NCT00919503Phase 2Completed

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Role: collaborator

NCT02308553Phase 1Completed

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Role: collaborator

NCT00822393Phase 3Completed

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Role: lead

NCT02333058Phase 2Completed

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

Role: lead